Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about Sphingolipid: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
Sphingolipid is a biological pathway involved in neurodegeneration research. Key relationships include: activates, associated with, therapeutic target. Associated with ALS, Aging, Als. Connected to 187 entities in the SciDEX knowledge graph.
| Name | Sphingolipid |
| Summary | Page for Sphingolipid Metabolism in Neurodegeneration |
| Key Genes/Proteins | APOPTOSIS, INFLAMMATION, CERS2, REL |
| Related Diseases | Als, Inflammation, Ms |
| Linked Hypotheses | 4 hypotheses |
Knowledge base pages for this entity
graph TD
CERS2["CERS2"] -->|"regulates"| Sphingolipid["Sphingolipid"]
REL["REL"] -->|"regulates"| Sphingolipid["Sphingolipid"]
CERS2_1["CERS2"] -->|"interacts"| Sphingolipid["Sphingolipid"]
Inflammation["Inflammation"] -->|"associated"| Sphingolipid["Sphingolipid"]
style Sphingolipid fill:#1b5e20,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0| Target | Relation | Type | Str |
|---|---|---|---|
| ENDOPLASMIC RETICULUM STRESS | inhibits | concept | 0.50 |
| STEM CELLS | inhibits | concept | 0.50 |
| ENDOPLASMIC RETICULUM | inhibits | concept | 0.50 |
| MTOR SIGNALING | activates | concept | 0.50 |
| ALZHEIMER'S | associated_with | concept | 0.50 |
| SGMS1 | regulates | concept | 0.50 |
| PARKINSON'S | associated_with | concept | 0.50 |
| 6-OHDA | associated_with | concept | 0.50 |
| Proteins | inhibits | protein | 0.50 |
| Pulmonary Fibrosis | activates | disease | 0.50 |
| ALZHEIMER'S | regulates | concept | 0.50 |
| Source | Relation | Type | Str |
|---|---|---|---|
| APOPTOSIS | activates | gene | 0.80 |
| INFLAMMATION | activates | gene | 0.80 |
| Als | activates | disease | 0.80 |
| Als | associated_with | disease | 0.80 |
| INFLAMMATION | therapeutic_target | gene | 0.80 |
| Inflammation | therapeutic_target | disease | 0.80 |
| Inflammation | associated_with | disease | 0.70 |
| INFLAMMATION | associated_with | gene | 0.70 |
| Inflammation | activates | disease | 0.70 |
| APOPTOSIS | therapeutic_target | gene | 0.70 |
| Als | therapeutic_target | disease | 0.70 |
| CERS2 | regulates | gene | 0.60 |
| REL | regulates | gene | 0.60 |
| CERS2 | interacts_with | gene | 0.60 |
| Ms | regulates | disease | 0.60 |
| GENES | contributes_to | gene | 0.60 |
| TNF | contributes_to | gene | 0.60 |
| MIRNAS | associated_with | gene | 0.60 |
| P53 | contributes_to | gene | 0.60 |
| Lymphoma | contributes_to | disease | 0.60 |
| Cancer | associated_with | disease | 0.60 |
| Als | contributes_to | disease | 0.60 |
| Tumor | contributes_to | disease | 0.60 |
| Ms | contributes_to | disease | 0.60 |
| CERS2 | associated_with | gene | 0.60 |
| REL | associated_with | gene | 0.60 |
| CLOCK | regulates | gene | 0.60 |
| GENES | regulates | gene | 0.60 |
| REST | regulates | gene | 0.60 |
| LC3B | activates | gene | 0.60 |
| P62 | activates | gene | 0.60 |
| MTOR | activates | gene | 0.60 |
| MERTK | activates | gene | 0.60 |
| AKT | activates | gene | 0.60 |
| MAF | activates | gene | 0.60 |
| PI3K | expressed_in | gene | 0.60 |
| AKT | expressed_in | gene | 0.60 |
| CANCER | associated_with | gene | 0.60 |
| APOPTOSIS | contributes_to | gene | 0.60 |
| OXIDATIVE STRESS | activates | gene | 0.60 |
| ERK | activates | gene | 0.60 |
| UGCG | associated_with | gene | 0.60 |
| LAMP1 | interacts_with | gene | 0.60 |
| PARKINSON'S DISEASE | therapeutic_target | gene | 0.60 |
| GBA1 | inhibits | gene | 0.60 |
| AUTOPHAGY | inhibits | gene | 0.60 |
| GBAP1 | regulates | gene | 0.60 |
| GBA | regulates | gene | 0.60 |
| ENO1 | biomarker_for | gene | 0.60 |
| MAP2K1 | biomarker_for | gene | 0.60 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Sphingolipid Metabolism Reprogramming | 0.443 | neurodegeneration | 4R-tau strain-specific spreading pattern |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-04 | 0 hypotheses
neurodegeneration | 2026-04-01 | 12 hypotheses Top: 0.648
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| EMP1 safeguards hematopoietic stem cells by suppressing sphingolipid metabolism [PMID:40624017] | Li L, Lei Y, Li Y, Xie Y, Hui P, Zang X, | Nat Commun | 2025 | 1 |
| IL-10 constrains sphingolipid metabolism to limit inflammation. [PMID:38383790] | York AG, Skadow MH, Oh J, Qu R, Zhou QD, | Nature | 2024 | 1 |
| PAQR4 regulates adipocyte function and systemic metabolic health by mediating ce [PMID:38961186] | Zhu Q, Chen S, Funcke JB, Straub LG, Lin | Nat Metab | 2024 | 1 |
| Sirtuin 1 mediated ceramide metabolism regulates intestinal mechanical barrier f [PMID:41856194] | Ma X, Liu Q, Mai K, Zhang Y | Int J Biol Macromol | 2026 | 0 |
| Metabolic abnormalities and reprogramming in cats with naturally occurring hyper [PMID:39499136] | ["Li Q", "Homilius M", "Achilles E", "Ma | ESC heart failure | 2025 | 0 |
| Reduced circulating sphingolipids and CERS2 activity are linked to T2D risk and [PMID:39792658] | Khan SR, Ye WW, Van JAD, Singh I, Rabiee | Science advances | 2025 | 0 |
| Very long-chain fatty acids drive 1-deoxySphingolipid toxicity. [PMID:41298489] | ["Majcher A", "Karsai G", "Yusifov E", " | Nature communications | 2025 | 0 |
| A multi-omics approach identifies the key role of disorders of sphingolipid meta [PMID:39638825] | ["Qu Y", "Ma D", "Wu T", "Wang H", "Tian | Scientific reports | 2024 | 0 |
| Disruption of adipocyte HIF-1α improves atherosclerosis through the inhibition o [PMID:35847503] | Wang P, Zeng G, Yan Y, Zhang SY, Dong Y, | Acta pharmaceutica Sinica. B | 2022 | 0 |
| Fumonisin B [PMID:35777715] | ["Li M", "Liu S", "Tan L", "Luo Y", "Gao | Food and chemical toxicology : | 2022 | 0 |
| Omega-3 polyunsaturated fatty acids reverse the impact of western diets on regul [PMID:35985403] | ["Camacho-Mu\u00f1oz D", "Niven J", "Kuc | Biochemical pharmacology | 2022 | 0 |
| Metabolic Reprogramming-A New Era How to Prevent and Treat Graft Versus Host Dis [PMID:33343357] | ["Kumari R", "Palaniyandi S", "Hildebran | Frontiers in pharmacology | 2020 | 0 |
| Evolution to the rescue: using comparative genomics to understand long non-codin [PMID:27573374] | ["Ulitsky I"] | Nature reviews. Genetics | 2016 | 0 |
| New insights into the organ-specific adverse effects of fumonisin B1: comparison [PMID:25155190] | ["Loiseau N", "Polizzi A", "Dupuy A", "T | Archives of toxicology | 2015 | 0 |
| Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Cl [PMID:25452455] | ["Stoffel E", "Mangu P", "Gruber S", "Ha | Journal of clinical oncology : | 2015 | 0 |
| Ceramide synthase 4 deficiency in mice causes lipid alterations in sebum and res [PMID:24738593] | ["Ebel P", "Imgrund S", "Vom Dorp K", "H | The Biochemical journal | 2014 | 0 |
| Modulation of serines 17 and 24 in the LC3-interacting region of Bnip3 determine [PMID:23209295] | ["Zhu Y", "Massen S", "Terenzio M", "Lan | The Journal of biological chem | 2013 | 0 |